Investor Relations

Merrimack is a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of cancer. Merrimack applies its systems biology-based approach to biomedical research, throughout the research and development process. Merrimack currently has six targeted therapeutic oncology candidates in clinical development.

View all »   RSSRecent Releases

Dec 17, 2014
Merrimack Pharmaceuticals Announces the Addition of Russell T. Ray to Its Board of Directors

Dec 12, 2014
Merrimack Pharmaceuticals Presents Research on Innovative Pipeline for Patients With Breast Cancer at the 2014 San Antonio Breast Cancer Symposium

Dec 4, 2014
Video Release -- Preclinical Research Differentiating the Activity of Merrimack's MM-398, Nanoliposomal Irinotecan (nal-IRI), Published in Cancer Research

Dec 1, 2014
Merrimack Pharmaceuticals to Present at Oppenheimer 25th Annual Healthcare Conference, Hold Analyst Day and Present Research on Multiple Molecules in December 2014

Stock Quote (NASDAQ: MACK)

Price:
10.53

Change:
+ 0.11

Day High:
10.55

Day Low:
10.25

Volume:
379,700

10:23 AM ET on Dec 19, 2014
Delayed ~20 min. By eSignal.

Shareholder Tools